JTCS St. Jude Medical
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mertens, L.
Right arrow Articles by Gewillig, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mertens, L.
Right arrow Articles by Gewillig, M.

J Thorac Cardiovasc Surg 1998;115:1063-1073
© 1998 Mosby, Inc.


SURGERY FOR CONGENITAL HEART DISEASE

Protein-losing enteropathy after the Fontan operation: An international multicenter study

Luc Mertens, MD, PhDa, Donald J. Hagler, MDb, Ursula Sauer, MDc, Jane Somerville, MDd, Marc Gewillig, MD, PhDa

Sponsored in part by The Belgian Foundation for Research in PediatricCardiology.

From the Department of Pediatric Cardiology, UZ Leuven, Leuven, Belgiuma;the Department of Pediatric Cardiology, Mayo Clinic, Rochester, Minn.b;Deutsches Herzzentrum, München, Germanyc; and Grown UpCongenital Heart Unit, Royal Brompton and National Heart Hospital, London,United Kingdom.d

Received for publication July 16, 1997. Revisions requested August 25, 1997. Revisions received Nov. 17, 1997. Accepted for publication Nov. 20, 1997. Address for reprints: Marc Gewillig, MD, Pediatric Cardiology,University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium.


    Abstract
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Conclusion: Therapeutic...
 Appendix: List of participating...
 References
 
Objective: This multicenter studyretrospectively analyzes the data on 114 patients with protein-losingenteropathy after Fontan-type surgery. Special attention was given to thedifferent treatment strategies used and their effect on outcome.
Methods and results: In 35 participating centers 3029Fontan operations were performed. The incidence of protein-losing enteropathy inthe survivors was 3.7%. The median age at Fontan-type surgery was 8.2years (range: 0.6 to 32.9 years). Median age at diagnosis of protein-losingenteropathy was 11.7 years with a median time interval between surgery anddiagnosis of 2.7 years (range: 0.1 to 16.4 years). Most patients had edema (79%)and effusions (75%). Hemodynamic data revealed a mean right atrialpressure of 17 ± SD 5.3 mm Hg with a cardiac index of 2.4 ±0.8 L/min/m2. Medical treatment only (n =52) resulted in a complete resolution of symptoms in 25%, no improvementin 29%, and death in 46%. Surgical treatment (n =52) was associated with relief of protein-losing enteropathy in 19%, noimprovement in 19%, and death in 62%. In 13 patients 16percutaneous interventions were performed. This resulted in symptomaticimprovement after 12 interventions and no improvement after 4 interventions.
Conclusions: We conclude that the currenttreatment of protein-losing enteropathy after Fontan operation is associatedwith a very high mortality and morbidity rate. Preventive strategies and newtherapeutic approaches are necessary. (J Thorac Cardiovasc Surg1998;115:1063-73)


    Introduction
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Conclusion: Therapeutic...
 Appendix: List of participating...
 References
 
Protein-losing enteropathy (PLE) is a rare but life-threateningcomplication after the Fontan operation. It is speculated that the elevatedsystemic venous pressures associated with the Fontan circulation cause theintestinal protein loss by increased pressures in the enteric lymphatic system.

Only limited information is presently available on the incidence, thepredisposing factors and the hemodynamic profile of patients who have had theFontan operation and in whom PLE develops.Go Go 1,2 Different treatment strategieshave been proposed for PLE after the Fontan operation, but their effect on theoutcome remains largely unknown. Reports on successful management are limited.For the management of these difficult conditions it is, however, crucial to knowwhich approach is doomed to fail so that alternative treatment options can beexplored. The present study is a retrospective multicenter study reviewing theincidence, hemodynamics, treatment strategies, and outcome of patients with PLEafter Fontan-type surgery.


    Materials and methods
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Conclusion: Therapeutic...
 Appendix: List of participating...
 References
 
Center recruitment.
This study is a retrospective multicenter study. The centers wererecruited either by e-mail through Pediheart (a server to which professionalsinvolved in the health care of patients with congenital heart disease cansubscribe pediheart@medisun.ucsfresno.edu])or by regularmail. At the time the study was announced, 588 persons received the e-mailmessage. Regular mailing was sent to all 470 members of the European Associationof Pediatric Cardiologists. Thirty-five centers (listed at the end of the paper)finally submitted data. Collection of data was started in August 1995 andstopped in December 1996.

Patient selection.
A study questionnaire was filled out for each patient who had hadFontan-type surgery and in whom clinical symptoms of documented hypoproteinemia(edema, effusions) due to PLE developed. Other causes of hypoproteinemia such asliver failure and renal protein loss needed to be excluded.

In addition, the centers were asked to submit data as to the number ofFontan operations that had been performed, perioperative mortality rates, andfollow-up procedures. This allowed an assessment of the incidence of PLE afterFontan-type surgery. Because of incomplete data sets, detailed information couldnot be gathered on the other patients without PLE who have had Fontanoperations.

Fontan surgery.
Descriptive statistics were performed on the data. The primary outcomevariable was the effect of treatment on the PLE (death, no change, improved,cured). In every patient with PLE, all the requested information was obtained.Student's t test, {chi}2 test, correlation analysis withFisher's r to z transformation were applied where appropriate. Survival analysiswas performed by the Kaplan-Meier estimation. For the comparison of subgroupsurvival Mantel-Cox log rank analysis was performed. Statistical analysis wasperformed with the software programs Statview 4.5 (Abacus Concepts, Berkeley,Calif.) and GB-stat 6.0 (Dynamic Microsystems, Silver Spring, Md.).


    Results
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Conclusion: Therapeutic...
 Appendix: List of participating...
 References
 
General patient data.
In total, 3029 Fontan-type operations were performed in 35 participatingcenters. The operations were performed between 1975 and 1995. The number ofFontan operations performed in each center ranged between 4 and 839 (median:54). The early mortality rate (<30 days after surgery) ranged between 0%and 41.7 %, with a mean of 13.3  ± standard deviation 9.5%.The total number of patients in follow up who have undergone Fontan operationswas 2584 (median for each center: 40; range: 3 to 764 patients). PLE wasdiagnosed in 114 patients. The 3.8% incidence of PLE is relative to thetotal number of Fontan-type operations and 4.2% relative to the number ofearly survivors. The incidence of PLE relative to the total number of Fontanoperations in each center varied between 0% and 25%. Neither thenumber of Fontan operations performed in each center nor the early mortalityrates correlated significantly with the incidence of PLE.

Data on all 114 patients with PLE were obtained (72 male and 42 female).The cardiac diagnosis was tricuspid atresia in 36 patients (31.6%),double-inlet left ventricle in 33 patients (29%), and other forms of"complex univentricular heart" in 45 patients (39.4%). Thelast group contained diverse complex congenital heart defects such asatrioventricular canal–type of malformation (8), double-outlet rightventricle (8), mitral atresia (4), single-inlet ventricle (4),L-transposition of the great arteries plussevere pulmonary stenosis (4), double-inlet right ventricle (2), hypoplasticleft heart syndrome (2), pulmonary atresia with intact ventricular septum (2),and other forms of "functional univentricular heart" (10).

Heterotaxy syndrome was present in three patients: two patients withasplenia and one patient with polysplenia. Four patients had situs inversus, andone patient had situs ambiguus.

In 97 of 114 patients (85%) palliative surgery was performedbefore the Fontan operation. The different types of pre-Fontan palliation andthe age at which pre-Fontan surgery was performed are summarized in Table I.In total, 62 of 114 (53%) patients, when initially seen, had lowpulmonary blood flow that caused cyanosis; 33 of 114 (28%) patients hadhigh pulmonary blood flow that required a banding type of operation to protectthe pulmonary circulation. In this series, initial banding was performed at amedian age of 0.6 years (range: 3 days to 3.4 years); five patients were bandedtwice. In 19 of 114 (19%) patients, the initial lung flow was "balanced"and surgical palliation before the Fontan operation was not performed.


View this table:
[in this window]
[in a new window]
 
Table I. Pre-Fontan surgery
 
Pre-Fontan hemodynamic data.
A preoperative cardiac catheterization was performed in 106 of 114patients (93%). Table II summarizes the hemodynamic measurements obtainedbefore the Fontan operation.Data on preoperative atrioventricular valve regurgitation were available on 92patients. Of 92 patients, atrioventricular valve regurgitation was described asabsent in 64 (69.5%) patients, mild in 18 (19.5%) patients,moderate in 5 (5.5%) patients, and severe in 5 (5.5%) patients.


View this table:
[in this window]
[in a new window]
 
Table II. Pre-Fontan hemodynamic data
 
Fontan-type surgery.
Fontan-type surgery was performed at a median age of 8.2 years (range:0.6 to 32.9 years). The operation was performed in 70 of 114 patients (61.4%)before 1987 and in 44 of 114 patients (38.6%) after 1987.

The time distribution of the series reflects changes in surgicaltechniques. In 114 patients, an atrioventricular connection was performed in 22(19.3%); an atriopulmonary connection was performed in 75 (65.8%);and a total cavopulmonary connection (with total or subtotal exclusion of theright atrium) was performed in 17 (14.9%). Thus no type of connection isfree of PLE after Fontan surgery.

The early postoperative course was characterized by a median intensivecare unit stay of 8 days (range: 2 to 50 days), a median postoperativehospitalization duration of 26 days (range: 8 to 150 days), and a requirementfor chest tube drainage during 12 days (median range: 0 to 135 days).Postoperative complications were ascites (n = 17), renal failure (n = 13), arrhythmia(n = 26), respiratory problems (n = 8), wound infection (n =5), unilateral diaphragmatic paralysis (n =3), and neurologic complications (n = 2).

In 12 patients additional surgery was performed between the initialFontan operation and the time PLE was diagnosed. This included closure of a leakin the atrioventricular-valve patch (4), atrioventricular-valve replacement (3),pacemaker implantation (3), plication of the diaphragm (1), and aortic valvereplacement (1). In one patient angioplasty of the pulmonary artery wasperformed.

Clinical diagnosis of PLE and hemodynamic evaluation.
As mentioned in the Materials and methods section, PLE was defined inthis study as the occurrence of clinical symptoms related to documentedhypoproteinemia caused by intestinal loss. Other causes of hypoproteinemia hadto be excluded. Moreover, subclinical gastrointestinal protein loss was notconsidered an inclusion criterion for the present study.

At the time of diagnosis of PLE, the patients had edema (79%),ascites (53%), pleural effusion(s) (22%), and/or chronic diarrhea(11%). Other symptoms or clinical findings present at the time ofdiagnosis were dyspnea (5%), fatigue (3.5%), abdominal fullness (5%),carpopedal spasms (1.7%), and a pericardial effusion (1.7%). Theother complications are summarized in Table III.


View this table:
[in this window]
[in a new window]
 
Table III. Other complications inpatients with PLE
 
The median time interval between Fontan-type surgery and the occurrenceof PLE was 2.7 year (range: 1 month to 16.4 years).

In all patients either total protein and/or serum albumin measurementswere obtained. In 89 of 114 patients the serum albumin level at the time ofdiagnosis was 2.4 ± 0.6 gm/dl (normal value: 3.5 to 5.5 gm/dl). In55 of 114 patients the total protein level was 4.3 ± 0.8 gm/dl(normal value: 5.5 to 8.0 gm/dl). The gastrointestinal protein loss wasquantified by calculating the {alpha}1-antitrypsin clearance in 27patients. The mean value was 432 ± 370 ml/24 hr (normal value <27 ml/24 hr). In seven patients gastrointestinal protein loss was quantified byintravenously administered 51chromium-labeled albumin. An increasedenteric protein loss was demonstrated by an increased excretion of the labeledalbumin in the stools: 22.7% ± 7.2% of the injectedradioactive label (normal: <2.0%).

In 83 (73%) of 114 patients hemodynamic evaluation by cardiaccatheterization was performed after PLE was diagnosed. Table IV summarizes thebasic hemodynamic measurements obtained during catheterization.These data are, however, difficult to interpret because nearly all of thepatients were receiving significant doses of diuretics at the time ofcatheterization. Of special note are the mean cardiac index of 2.4 ± 0.8 L/kg/min and the mean right atrial pressure of 17.0 ±5.3 mm Hg. In 29 patients a gradient was reported to be present in some part ofthe Fontan connection. In 22 patients numeric data for gradients were available(mean: 4.3 ± 3.0 mm Hg; range: 2 to 15 mm Hg). Other findings ofrelevance included intrapulmonary shunting (5), residual connection singleventricle–pulmonary artery (3), atrioventricular valve patch leak (1),obstruction of pulmonary venous return (2), obstruction of the atrial bafflefrom the hepatic veins to the pulmonary artery (1), venovenous collaterals (3),residual Blalock-Taussig shunt (1), diaphragmatic paralysis (3), and coronaryartery ligation (1). Atrioventricular valve regurgitation was present in 29patients (severe [5], moderate [12], and mild [12]). Ventricular dysfunction waspresent in 24 patients (severe [9], moderate [9]). In two patients a markedbradycardia associated with sinus node dysfunction and nodal rhythm was present.


View this table:
[in this window]
[in a new window]
 
Table IV. PLE hemodynamic data
 
Treatment and outcome of PLE.
Patients in whom PLE develops after the Fontan operation have a poorprognosis with a 5-year survival of 59% and a total mortality rate of 50%in the present study. The Kaplan-Meier survival analysis is shown in Fig. 1.



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1. Survival analysis(Kaplan-Meier) of patients with PLE. The graph represents a Kaplan-Meiersurvival analysis. Time zero represents thedate of diagnosis of PLE. The vertical barsrepresent the 95% confidence interval.

 
In the treatment of PLE, a wide variety of different approaches have beentried. Three main treatment options can be identified. First, a purelynoninvasive treatment consisting of drug treatment (diuretics, afterloadreduction, inotropic agents, and steroids) and diet (low fat and high protein)and/or protein infusions can be used. Second, surgery can be performed toimprove the Fontan hemodynamics. Third, a nonsurgical interventional approachcan be used, including fenestration of the atrial septum and balloon dilation ofa pathway obstruction.

In our patient population, 52 (45.6%) patients were treatednoninvasively, 52 (45.6%) patients received a surgical intervention, and10 (8.8%) patients received a percutaneous intervention.

Medical treatment only was given to 52 patients. An overview oftreatments used in this group is shown in Table V.Most patients were treated with a combination of diuretics, digoxin, afterloadreduction, and diet. Albumin infusions were given intermittently in 28 of 52patients. Additional medication was given to 32 of 52 patients. This medicalapproach resulted in a subjective improvement with resolution of the PLEsymptoms in 13 of 52 (25%) patients. In 15 of 52 (28.8%) patientssome improvement was observed, but the patients remained symptomatic (alive withPLE). Twenty-four (46.2%) patients from this treatment group died.


View this table:
[in this window]
[in a new window]
 
Table V. Overview of medical treatment
 
Surgery was performed in 52 of 114 patients. The median interval betweenthe diagnosis of PLE and surgery was 1.0 year (range: 0.01 to 8.0 years). Themedian age at operation was 14.6 years (range: 2.5 to 45.3 years). The intervalbetween the Fontan operation and the redo operation for PLE was 4.5 years(range: 0.6 to 16.5 years). A wide variety of surgical approaches were tried(Table VI). The first type ofoperation was surgery aimed at optimizing the Fontan circuit either by conduitsurgery, valve surgery, or ventricular septal defect surgery. A second type ofoperation involved the conversion of a type of Fontan circuit (for example,atrioventricular connection converted into atriopulmonary connection). Thisoperation was performed either because of a mechanical problem with the existingFontan circuit or because the new type of circuit was thought to behemodynamically more favorable. A third type of operation is defined as a Fontantakedown. In a fourth subgroup of patients, heart transplantation was performed.


View this table:
[in this window]
[in a new window]
 
Table VI. Different types of operations
 
The outcome of surgery is presented in Table VII.A very high overall mortality rate (61. 5%) is associated with PLEsurgery. Most of the deaths occur in the early postoperative period (81%within 3 months after the operation). Although the groups are relatively small,all different surgical approaches seem to result in a poor outcome. Even hearttransplantation appeared to have a high mortality rate, with two deaths in fivepatients. There is also one patient in whom the PLE symptoms did not resolveafter transplantation.


View this table:
[in this window]
[in a new window]
 
Table VII. Outcome of surgery
 
In 13 patients interventional catheterization were performed. In threepatients the interventional approach was combined with a surgical approach.Three types of interventional procedures were performed in the patients withPLE. The first type involved a balloon dilation with or without stenting of astenosis on the Fontan-type connection or of a stenosis on the pulmonary artery(nine interventions). The second type of intervention involved percutaneouslycreating a fenestration in the intraatrial septum (five interventions). In onepatient, systemic–pulmonary artery collaterals were occluded with coils.

Nine balloon dilations with four stent placements were performed, threebecause of a stenosis in the Fontan circuit and six for a stenosis in apulmonary artery. The mean gradient before balloon dilation was 4.8 ±4.4 mm Hg that was reduced to 2.0 ± 1.9 mm Hg after the procedures.In eight cases the procedure was considered successful with a significantdecrease in gradient or in increase in blood flow. In one patient a balloondilation of the inferior cavopulmonary anastomosis was unsuccessful with noreduction in gradient. Of the eight successful procedures, three had no effecton PLE and three resulted in a long-lasting symptomatic improvement (in onepatient this occurred after further surgery); in two patients only a temporaryimprovement was obtained with a recurrence of PLE symptoms within a few monthsafter the procedure.

Five fenestrations in the intraatrial septum were created percutaneouslywith different techniques. In three patients the fenestration was created byblade septectomy combined with progressive balloon dilation of the fenestration.In one patient the intraatrial septum was punctured, and progressive balloondilations of the puncture hole were performed. In one patient a stent was placedin the fenestration. The time interval between the diagnosis of PLE and thefenestration was 1.6 years (median range: 0.2 to 5.1 years). The median age atfenestration was 17.9 years (range: 2.8 to 41.7 years). The median time intervalbetween the creation of the fenestration and the time of Fontan surgery was 8.5years (range: 1.6 to 10.7 years). In three of the five patients a marked effectwas observed on the PLE symptoms with nearly complete resolution of allsymptoms. In the remaining two patients only a mild improvement was observed. Intwo patients a stroke occurred after the fenestration was created. One of thesepatients was not given anticoagulants after the fenestration.

In one patient systemic–pulmonary artery collaterals were closed bycoil placement, but this did not improve intestinal protein loss.

Fig. 2 represents the Kaplan-Meier survival analysis for the threedifferent treatment groups. Log rank analysis could not demonstratea significant effect of treatment option on PLE survival (Table VIII).



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2. Survival analysis ofdifferent treatment groups. A Kaplan-Meier analysis of the different treatmentsubgroups is represented. Time zero representsthe date of diagnosis of PLE. Log rank analysis did not show a significanteffect of treatment on survival.

 

View this table:
[in this window]
[in a new window]
 
Table VIII. Final outcome of PLE
 
The effect of steroid treatment on PLE.
Because steroids have been added to the treatment in the differenttreatment groups, their effect on PLE is discussed separately. Steroids havebeen added to the treatment in 16 patients. Seven patients in the surgicaltreatment group received steroids: five patients before the intervention and twopatients after the operation. It is evident that in those patients in whomsurgery was performed after steroid treatment, steroid treatment was notsufficiently effective. Six patients of the interventional catheterization groupwere also treated with steroids. Four patients received steroids after theintervention and two patients before it. In three patients of themedication-only group, steroids were added to the treatment. All patients weretreated with reducing dosing schemes. Steroid treatment resulted in a markedsymptomatic improvement in 5 of 16 patients, with nearly complete disappearanceof all PLE symptoms. Four of these patients, however, required prolongedadministration of a low maintenance dose. In 7 of 16 patients some subjectivesymptomatic improvement was obtained without complete disappearance of all PLEsymptoms. In four patients no effect could be noted.


    Discussion
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Conclusion: Therapeutic...
 Appendix: List of participating...
 References
 
This multicenter study summarizes the clinical characteristics andtreatment outcomes of patients with PLE after Fontan-type surgery. It confirmsthat PLE is a rare complication after Fontan-type surgery that is associatedwith a poor prognosis. Whatever treatment strategy is used, the prognosis ofpatients with PLE after Fontan-type surgery is poor.

Clinical characteristics of patients in whom PLE develops after Fontansurgery.
In a recent study Feldt and associatesGo 1 overviewed the clinicalcharacteristics of the Mayo Clinic patients in whom PLE developed after a Fontanoperation. They studied a total of 427 patients who survived for 30 days after aFontan operation performed between July 1973 and January 1987. In 47 of 427 (11%)patients PLE developed during follow up. Univariate and multivariate analysisindicated that the factors associated with the development of PLE wereventricular anatomy (other anatomy than dominant left ventricle), increasedpreoperative ventricular end-diastolic pressure, longer operative bypass time,increased length of hospital stay, and postoperative renal failure. In thepresent study a multivariate analysis could not be performed because the data onthe patients in whom PLE did not develop after Fontan surgery could not beobtained. However, in the patients described in the present study (which alsoincludes the Mayo Clinic data), several of these risk factors seem to bepresent.

The preoperative hemodynamic evaluation shows that some of the patientsin whom PLE develops after Fontan surgery would nowadays no longer be scheduledfor Fontan surgery (for instance, a patient with a pulmonary vascular resistanceof 5.6 units/m2 or a patient with a mean pulmonary artery pressureof 41 mm Hg). Because some of these patients had been initially treated in thepre-Fontan era, the pre-Fontan palliations used reflect a historical evolutionin the treatment of univentricular hearts. This is demonstrated by the widevariation of different initial palliative techniques, with some patients havinghad suboptimal pre-Fontan procedures with poor timing (banding at 0.9 ±0.9 year). This resulted in prolonged and excessive volume loading of theventricle and elevated pulmonary vascular resistance in some of the laterpatients with PLE. This certainly contributed to a difficult early postoperativecourse in some of these patients (such as, with pleural effusions, renalfailure). Although we have no reference values, a mean hospitalization stay of26 days seems long after a Fontan operation.

Remarkable in the present study is the predominance of patients with aleft ventricular morphologic condition (68%), with only 18% of allpatients with PLE having a right ventricular morphologic condition. In 14%of all patients ventricular morphologic condition could not be determined. Thisdistribution is to be compared to the whole Fontan population, but it shows thatfurther study is required to better identify the risk factors associated withPLE.

PLE hemodynamics and pathophysiology.
PLE in cardiac disease is mostly associated with disorders in whichchronically elevated systemic venous pressures and especially elevated superiorcaval venous pressures are present (constrictive pericarditis,Go 4 long-standing congestive heartfailure,Go 5 baffle obstructionafter the Mustard operation for transposition of the great arteriesGo 6; after the Glenn operationGo 7 and Fontan operationGo Go Go Go 1,2,8-11).The exact pathophysiology of PLE is unknown. It is hypothesized that chronicvenous congestion with elevated superior vena caval pressures leads to disturbedlymph drainage through the thoracic duct.Go 10Moreover, the increased inferior vena caval and portal vein pressures lead toincreased intestinal congestion and lymph production. Proteins and lymphocytesleak from the dilated lymphatics. This functional disorder may progress tointestinal lymphangiectasia. Maybe an inflammatory response caused by chroniccongestion or leakage of proteins from the enteric lymphatic system is alsoinvolved in the pathogenetic process. The beneficial therapeutic effect ofsteroids observed in some patients could be explained by suppression of thisinflammatory reaction.Go Go 12,14 No consistent effect ofsteroids can, however, be found, which indicates that additional mechanisms areprobably involved. The actual molecular basis for PLE remains unknown. It hasbeen shown that sulphated glycosaminoglycans may be important in regulatingvascular and renal albumin loss. In a recent paper three children with PLE wereshown to have an enteric heparin sulfate deficiency.Go 15 In those three infants a completeabsence of enterocyte heparin sulphate was found by histochemistry. The recentfinding that high molecular-weight heparin improves PLE after the FontanoperationGo 19 could beconsistent with this. Chronic congestion could interfere with the production anddistribution of heparin sulfate leading to intestinal albumin loss. Anotherpossibility is a disturbance in endothelial function in the lymphatic system.The exact pathophysiologic mechanism presently remains obscure and requiresfurther study. Especially the impact of chronically elevated systemic venouspressures on intestinal lymphatic functioning should further be explored inexperimental studies.

Because systemic venous pressure is the driving force for the pulmonarycirculation in a Fontan circulation, chronic venous congestion is alwayspresent. It is not known why intestinal protein loss therefore occurs in a smallpercentage of patients. Our data suggest that not only hemodynamic factors areinvolved in the process of PLE but that the complication may result from acombination of unfavorable factors. Increased systemic venous pressures arecertainly not the only underlying factor because, in 23% of the patientswith PLE in whom right atrial pressures were obtained, mean right atrialpressure was below 15 mm Hg (a "good" value for a patient after aFontan operation). Even in those patients where an unfavorable hemodynamicfactor was detected on hemodynamic evaluation (e.g., stenosis on the conduit),improvement of the hemodynamics (e.g., removal of the stenosis) did not alwaysresult in improvement of PLE. These are patients in whom the Fontan circulationis not tolerated without any good explanation. It may be that the intestinallymphatic system operates at the limit of its capacities in all patients afterthe Fontan operation but only fails in a small percentage of patients.Structural and physiologic differences in lymphatic function could explain theoccurrence of PLE but these are extremely difficult to study. Anotherpossibility is that the standard hemodynamic evaluation methods in thesepatients fail to uncover hemodynamic disturbances causing PLE. Especiallythe evaluation of right atrial pressures and pulmonary vascular resistance inpatients who have been aggressively treated with diuretics before the cardiaccatheterization is questionable. Other factors such as pulmonary vascularreactivity may not be adequately evaluated during catheterization.

PLE treatment and outcome.
Different treatment options have been tried in patients in whom PLEdevelops after the Fontan operation, but only a few successful approaches havebeen published.Go Go Go Go 12,14,16,20

Our patients experienced a wide variety of different treatmentstrategies. To organize the different treatment options, we categorized ourpatients into three different classes: purely medical treatment, surgicaltreatment, and treatment by interventional catheterization. This division issomewhat arbitrary, because all patients who underwent surgical treatment werealso receiving medication. Moreover the "surgery" group is a veryheterogeneous group going from Fontan redo surgery to Fontan takedown and hearttransplantation. No relation between strategy and outcome of PLE was observed.

Medical treatment was aimed at some symptomatic relief (diuretics,intermittent infusion of albumin) to improve hemodynamics (digitalis,ventricular afterload reduction), to influence an unknown mechanism (steroids),or to prevent further complications (antiarrhythmics, anticoagulation). Resultswere disappointing, and this probably reflects, in most cases, the naturalhistory of PLE after the Fontan operation.

Surgery in patients with PLE was associated with a very high mortalityrate. Especially in patients with ventricular dysfunction,atrioventricular-valve insufficiency, or increased pulmonary vascularresistance, mortality rate is extremely high. Poor hemodynamics and chronichypoproteinemia with resulting catabolism probably compromised the outcome ofmajor cardiac surgery. In this context it should be noted that a long timeinterval between the diagnosis of PLE and the time of surgery was observed inthe present study (mean: 1.8 years; range: 0.01 to 8.0 years). Reluctance of thecardiologist or the surgeon to perform major surgery in a "mildly"symptomatic patient probably caused a major delay in many cases. Of thosepatients with PLE who survived surgery, only 50% were cured of PLE aftersurgery. This could be due to insignificant improvement in hemodynamics aftersurgery. So, for instance, converting one type of Fontan circulation intoanother type of circuit may not result in a hemodynamic amelioration that issufficient to cure PLE. In vitro hemodynamic studies and computer simulationshave shown that some types of Fontan circuits are hemodynamically more favorablethan others.Go Go 20,23 It seems that if a patient isnot tolerating one type of circuit, the small differences in energy loss betweenthe different surgical connections may not really be clinically relevant. Alsothe changes in the enteric system may become irreversible and not responsiveeven to normalization of the hemodynamics. In one cardiac transplant patient,PLE resolved completely in the immediate postoperative period but recurred a fewyears after surgery despite good hemodynamics. Thus the effect oftransplantation on PLE after Fontan surgery also requires further study.

Because of the high risk associated with surgery, interventionalprocedures to optimize the Fontan circuit are a potential alternative. Differenttypes of interventions were performed. The balloon dilations and stentplacements resulted in symptomatic improvement in most patients. However, onlyone patient was actually considered as not having symptomatic protein loss afterthe procedure. Previous reports have already mentioned a beneficial effect offenestrating the intraatrial septum on PLE.Go Go Go 16-18,24 This is confirmed in thepresent study where a fenestration was performed with improved Fontanhemodynamics in five patients and reduced protein loss after the procedure inall patients. It is the only treatment where a consistent positive effect wasobserved. However, in two patients a thromboembolic event occurred withneurologic complications that indicated the absolute requirement foranticoagulation before and after the fenestration. Moreover, there was a hightendency for the percutaneous fenestrations to close spontaneously withdeterioration of PLE symptoms. Newer techniques like stent placement in theintraatrial septum could prevent this, but only limited experience is presentlyavailable.Go 25

Limitations of the study.
It is evident that this study has the limitations of any multicenterclinical study, such as center differences in patient evaluation. Moreover, thisstudy has the limitations of any retrospective study that comprisesincompleteness of data, making conclusions very difficult. An additionallimitation is the absence of a control group of patients who underwent a Fontanoperation and in whom PLE did not develop. Ideally we should have obtained dataon all 2854 patients who are still in follow-up in the 35 participating centers,but this was practically unfeasible. Maybe the creation of an internationalFontan registry could help for studying more rare complications of thisoperation.


    Conclusion: Therapeutic strategies for PLE after Fontan surgery
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Conclusion: Therapeutic...
 Appendix: List of participating...
 References
 
Because enteric lymphatic function is impossible to evaluate, only theFontan hemodynamics can be directly assessed after the diagnosis of PLE is made.Therefore, the moment the diagnosis is suspected, an immediate, careful,complete hemodynamic evaluation with catheterization is required. When ahemodynamic lesion that can be treated by therapeutic intervention (e.g.,pulmonary artery stenosis) is detected, this should be immediately managed.Fenestration should be considered if there is no residual lesion to treat. Fullanticoagulation is indicated before and after the fenestration. Surgery shouldbe performed before cachexia develops. Significant ventricular dysfunction oratrioventricular valve regurgitation are important contraindications forreoperation. The patient's general condition should be optimized before surgery.A trial with high-dose steroid treatment or subcutaneous high molecular weightheparin may be used. Heart transplantation should be considered before chronicPLE with eventual irreversible changes in the enteric lymphatic system develops.


    Appendix: List of participating physicians and centers
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Conclusion: Therapeutic...
 Appendix: List of participating...
 References
 
Australia: G. Sholler, New Children's Hospital, Sidney; Belgium: P. Viart, Hôpital Universitaire des Enfants Reine Fabiola, Brussels; H. Verhaaren, University Hospital Gent; M. Gewillig and L. Mertens, University Hospital Leuven (KU Leuven); Canada: I. Adatia, R. Freedom, Hospital for Sick Children, Toronto; Croatia: I. Malcic, University Hospital Rebro, Zagreb; Czech Republic: J. Hruda, Kardiocenter Prague; Denmark: J.R. Jacobsen, Rigshospitalet, Copenhagen; France: G. Vaksmann and J. Rey, Hôpital Universitaire de Lille; A.M. Worms, Hôpital d'Enfants, Nancy; J. Kachaner, Hôpital Necker, Paris; J. Martinez, Hôpital Pasteur, Toulouse; Germany: U.Sauer, Deutsches Herzzentrum MüAdunchen; F. Hentrich, University Hospital Essen; D. Bartmus and R. Buchhorn, University Hospital Göttingen; T. Paul, University Hospital Hannover; P. Schneider, J. Theile and I. Wagner, University Hospital Leipzig; Greece: S. Pallides, Thessaloniki Hospital; Italy: G. Vignati, Ospedale San Donato Milano; Japan: T. Shinohara, Tokyo Women's Medical College; Turkey: A. Sarioglu, Istanbul University Hospital; United Kingdom: E. Rosenthal, Guy's Hospital, London; J. Somerville, Royal Brompton Hospital (GUCH unit), London; N. Wilson, Royal Hospital for Sick Children, Glasgow; G. Stuart, University Hospital of Wales, Cardiff; United States: D.J. Hagler Mayo Clinic, Rochester; Dr. S. Gullquist, Medical College of Virginia, Richmond; H. Weber, Penn State University Children's Hospital, Hershey; T. Bricker, Texas Children's Hospital, Houston; J.M. Baffa, University of Maryland Medical Center, Baltimore; K.S. Rheuban, University of Virginia Health Sciences Center, Charlottesville; Spain: J. Casadaliga, Hospital Materno-Infantil Valle Hebron, Barcelona; Sweden: Dr. K. Hanseus, University Hospital Lund; The Netherlands: A. Cromme Dijkhuis, Sophia Children's Hospital Rotterdam


    Footnotes
 
On behalf of the PLE study group


    References
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 Conclusion: Therapeutic...
 Appendix: List of participating...
 References
 

  1. Feldt R, Driscoll D, Offord K, et al.Protein-losing enteropathy after the Fontan operation. J Thorac CardiovascSurg 1996;112:672-80.[Abstract/Free Full Text]
  2. Malcic I, Sauer U, Brodherr S, et al.Protein-losing enteropathy after Fontan operation (abstract). Cardiol Young 1995;5(suppl):S28.
  3. Cetta F, Feldt R, O'Leary P, et al.Improved early morbidity and mortality after Fontan operation: the Mayo Clinicexperience, 1987 to 1992. J Am Coll Cardiol 1996;28:480-6.[Abstract]
  4. Wilkinson P, Pinto B, Senior J. Reversibleprotein-losing enteropathy with intestinal lymphangiectasia secondary to chronicconstrictive pericarditis. n Engl J Med 1965;273:1178-81.
  5. Davidson J, Waldmann T, Goodman D, Gordon R.Protein-losing enteropathy in congestive heart failure. Lancet 1961;1:899-902.[Medline]
  6. Moodie D, Feldt R, Wallace R. Transientprotein-losing enteropathy secondary to elevated caval pressures and cavalobstruction after the Mustard procedure. J Thorac Cardiovasc Surg 1976;72:379-82.[Abstract]
  7. Gleason WJ, Roodman S, Laks H.Protein-losing enteropathy and intestinal lymphangiectasia after superior venacava–right pulmonary artery (Glenn) shunt. J Thorac Cardiovasc Surg 1979;77:843-6.[Medline]
  8. Davis C, Driscoll D, Perrault J, et al.Enteric protein loss after the Fontan operation. Mayo Clin Proc 1994;69:112-4.[Medline]
  9. Crupi G, Locatelli G, Tiraboshi R, VillaniM, De Tomassi M, Parenzan L. Protein-losing enteropathy after Fontan operationfor tricuspid atresia (imperforate tricuspid valve). Thorac Cardiovasc Surg 1980;28:359-63.[Medline]
  10. Hess J, Kruizinga K, Bijleveld CMA,Hardjowijono R, Eygelaar A. Protein-losing enteropathy after the Fontanoperation. J Thorac Cardiovasc Surg 1984;88:606-9.[Abstract]
  11. Thorne S, Hooper J, Somerville J.Gastrointestinal protein loss in long term survivors of the Fontan operation(abstract). Br Heart J 1995;73(suppl):55.
  12. Rothman A, Snyder J. Protein-losingenteropathy following the Fontan operation: resolution with prednisone therapy.Am Heart  J 1991;121:618-9.[Medline]
  13. Rychik J, Piccoli D, Barber G. Usefulnessof corticosteroid therapy for protein-losing enteropathy after the Fontanprocedure. Am J Cardiol 1991;68:819-21.[Medline]
  14. Zellers T, Brown K. Protein-losingenteropathy after the modified Fontan operation: oral prednisone treatment withbiopsy and laboratory proved improvement. Pediatr Cardiol 1996;17:115-7.[Medline]
  15. Murch S, Winyard P, Koletzko S, et al.Congenital enterocyte heparin sulphate deficiency with massive albumin loss,secretory diarrhoea, and malnutrition. Lancet 1996;347:1299-301.[Medline]
  16. Mertens L, Dumoulin M, Gewillig M.Percutaneous fenestration of the atrial septum reduces protein-losingenteropathy after the Fontan operation. Br Heart J 1994;72:591-2.
  17. Warnes C, Feldt R, Hagler D. Protein-losingenteropathy after the Fontan operation: successful treatment by percutaneousfenestration of the atrial septum. Mayo Clin Proc 1996;71:378-9.[Medline]
  18. Jacobs M, Rychik J, Byrum C, Norwood WJ.Protein-losing enteropathy after the Fontan operation: resolution after bafflefenestration. Ann Thorac Surg 1996;61:206-8.[Abstract/Free Full Text]
  19. Donnelly J, Rosenthal A, Castle V, HolmesR. Reversal of protein-losing enteropathy with heparin therapy in three patientswith univentricular hearts and Fontan palliation. J Pediatrics 1997;130:474-8.
  20. de Leval M, Kilner P, Gewillig M, Bull C.Total cavopulmonary connection: a logical alternative to atriopulmonaryconnection for complex Fontan operations. J Thorac Cardiovasc Surg 1988;96:682-95.[Abstract]
  21. de Leval M, Dubini G, Migliavacca F, et al.Use of computational flow dynamics in the design of surgical procedures:application to the study of competitive flows in cavopulmonary connections. J ThoracCardiovasc Surg 1996;111:502-13.[Abstract/Free Full Text]
  22. Van Haesdonck J, Mertens L, Montas G, etal. Comparison by computerized numeric modeling of energy losses in differentFontan connections. Circulation 1995;9(Suppl):II322-6.
  23. Sharma S, Goudy S, Walker P, et al. Invitro flow experiments for determination of optimal geometry of totalcavopulmonary connection for surgical repair of children with functional singleventricle. J Am Coll Cardiol 1996;27:1264-9.[Abstract]
  24. Rychik J, Suh E, Rome J, Jacobs M.Experience with late fenestration for complications after the Fontan operation(abstract). Circulation 1996;94(Suppl):I296.
  25. Gewillig M, Mertens L, Stockx L.Percutaneous fenestration of the atrial septum with a stent. Eur J CardiacInterventions 1995;4:122-5.



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al.
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease) Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., December 2, 2008; 52(23): e1 - e121.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al.
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Adults With Congenital Heart Disease) Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., December 2, 2008; 52(23): 1890 - 1947.
[Full Text] [PDF]


Home page
CirculationHome page
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al.
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Circulation, December 2, 2008; 118(23): e714 - e833.
[Full Text] [PDF]


Home page
CirculationHome page
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al.
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Circulation, December 2, 2008; 118(23): 2395 - 2451.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Simmonds, M. Burch, H. Dawkins, and V. Tsang
Heart transplantation after congenital heart surgery: improving results and future goals.
Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 313 - 317.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
S.-J. Kim, W.-H. Kim, H.-G. Lim, and J.-Y. Lee
Outcome of 200 patients after an extracardiac Fontan procedure
J. Thorac. Cardiovasc. Surg., July 1, 2008; 136(1): 108 - 116.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. M. Gersony
Fontan Operation After 3 Decades: What We Have Learned
Circulation, January 1, 2008; 117(1): 13 - 15.
[Full Text] [PDF]


Home page
CirculationHome page
P. Khairy, S. M. Fernandes, J. E. Mayer Jr, J. K. Triedman, E. P. Walsh, J. E. Lock, and M. J. Landzberg
Long-Term Survival, Modes of Death, and Predictors of Mortality in Patients With Fontan Surgery
Circulation, January 1, 2008; 117(1): 85 - 92.
[Abstract] [Full Text] [PDF]


Home page
MMCTSHome page
M. S. Sharma, M. Kostolny, M. R. de Leval, and V. T. Tsang
Surgical approaches for single ventricle palliation
MMCTS, October 18, 2007; 2007(1018): 2394.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Procelewska, J. Kolcz, K. Januszewska, T. Mroczek, and E. Malec
Coagulation abnormalities and liver function after hemi-Fontan and Fontan procedures -- the importance of hemodynamics in the early postoperative period
Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 866 - 872.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
C. H Kiesewetter, N. Sheron, J. J Vettukattill, N. Hacking, B. Stedman, H. Millward-Sadler, M. Haw, R. Cope, A. P Salmon, M. C Sivaprakasam, et al.
Hepatic changes in the failing Fontan circulation
Heart, May 1, 2007; 93(5): 579 - 584.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Khairy, N. Poirier, and L.-A. Mercier
Univentricular Heart
Circulation, February 13, 2007; 115(6): 800 - 812.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. E. Canter, R. E. Shaddy, D. Bernstein, D. T. Hsu, M. R.K. Chrisant, J. K. Kirklin, K. R. Kanter, R. S.D. Higgins, E. D. Blume, D. N. Rosenthal, et al.
Indications for Heart Transplantation in Pediatric Heart Disease: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young; the Councils on Clinical Cardiology, Cardiovascular Nursing, and Cardiovascular Surgery and Anesthesia; and the Quality of Care and Outcomes Research Interdisciplinary Working Group
Circulation, February 6, 2007; 115(5): 658 - 676.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
R. Fernandez, A. Ashraf, and L. S. Dure
Nutritional Vitamin D Deficiency Presenting as Hemichorea
J Child Neurol, January 1, 2007; 22(1): 74 - 76.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
O. Uzun, J. K. Wong, V. Bhole, and O. Stumper
Resolution of Protein-Losing Enteropathy and Normalization of Mesenteric Doppler Flow With Sildenafil After Fontan
Ann. Thorac. Surg., December 1, 2006; 82(6): e39 - e40.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Ono, D. Boethig, H. Goerler, M. Lange, M. Westhoff-Bleck, and T. Breymann
Clinical outcome of patients 20 years after Fontan operation -- effect of fenestration on late morbidity
Eur. J. Cardiothorac. Surg., December 1, 2006; 30(6): 923 - 929.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. M. Ostrow, H. Freeze, and J. Rychik
Protein-Losing Enteropathy After Fontan Operation: Investigations Into Possible Pathophysiologic Mechanisms
Ann. Thorac. Surg., August 1, 2006; 82(2): 695 - 700.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page